Gerhard Moser

Gerhard Moser

Auto-generated profile, based on publicly available information

Gerhard Moser

Department of Otorhinolaryngology, Head and Neck Surgery, Paracelsus Medical University, Salzburg, Austria

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2013 in The Laryngoscope
Verified
Journal Article
Closed access
TRThorsten Ropposch
Thorsten Ropposch
BSBernhard Steger
Bernhard Steger
CMCem Meço
Cem Meço
MEMartin Emesz
Martin Emesz
HRHerbert Reitsamer
Herbert Reitsamer
GMGerhard Moser
Gerhard Moser

8 May 2011 in Head & Neck Oncology
Verified
Journal Article
Open access
PDF file
KSKathrin Schwager
Kathrin Schwager
AVAlessandra Villa
Alessandra Villa
CRChristoph Rösli
Christoph Rösli
DNDario Neri
Dario Neri
MRMaria Rösli-Khabas
Maria Rösli-Khabas
GMGerhard Moser
Gerhard Moser
Background: The antibody-based targeted delivery of bioactive molecules to tumour vasculature is an attractive avenue to concentrate therapeutic agents at cancer sites, while sparing normal organs. L19, F8 and F16 are three fully human monoclonal antibodies, specific to splice isoforms of fibronectin and tenascin-C, which bind to sites of active tissue remodeling and which are currently in Phase I and II clinical trials as radio-immunoconjugates and immunocytokines in patients with cancer and arthritis. In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions. Methods: We performed a comparative immunofluorescence analysis with the L19, F8 and F16 antibodies in 40 freshly frozen human head and neck cancer specimens. Results: On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19. Interestingly, some specimens exhibited striking differences in staining by the three antibodies. Conclusions: These results suggests that an individualized treatment procedure (e.g., choice of L19, F8 or F16 based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the best possible antibody to any given patient.

1 July 2006 in Annals of Anatomy - Anatomischer Anzeiger
Verified
Journal Article
Closed access
MTMiklós Tóth
Miklós Tóth
AAAlán Alpár
Alán Alpár
GBGergely Bodon
Gergely Bodon
GMGerhard Moser
Gerhard Moser
LPLajos Patonay
Lajos Patonay

7 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTeresa Magnes
Teresa Magnes
TMThomas Melchardt
Thomas Melchardt
LWLukas Weiss
Lukas Weiss
CMChristof Mittermair
Christof Mittermair
DNDaniel Neureiter
Daniel Neureiter
AEAlexander Egle
Alexander Egle
Despite modern treatment approaches, survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remains low and it is difficult to identify patients who derive optimal benefit from treatment. We therefore analyzed which commonly available laboratory and clinical parameters may help improve the prognostication in this patient group. This retrospective monocenter analysis includes 128 patients with recurrent or metastatic SCCHN treated with cetuximab alone or in combination with polychemotherapy as first line therapy. Factors with independent prognostic power in the multivariate analysis were used to build up a score separating patient groups with different survival. Patients had a median age of 61 years and 103 patients were treated with polychemotherapy plus cetuximab. An ECOG score above 1, high CRP and leukocyte levels, less intensive treatment and a time below 12 months from primary diagnosis to relapse remained as independent negative prognostic factors in multivariate analysis. Patients with 0 to 1 risk factors had a median OS of 13.6 months compared to a median OS of less than one month for patients 4 to 5 risk factors (p<0.001). This study identifies 5 clinical and serum values that influence survival of patients with recurrent or metastatic SCCHN treated with cetuximab. By combining these factors to create a score for OS, it is possible to distinguish a group of patients with significantly improved survival and define those most likely to have no benefit from cetuximab treatment.

1 January 1997 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
GMG. Moser
G. Moser
GOG. Oberascher
G. Oberascher

1 March 2011 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
DNDaniel Neunhaeuserer
Daniel Neunhaeuserer
MZMichaela Zebedin
Michaela Zebedin
MOMagdalena Obermoser
Magdalena Obermoser
GMGerhard Moser
Gerhard Moser
MTMark Tauber
Mark Tauber
SGStefan Galler
Stefan Galler